Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

May Validate Small Molecule Platform

Sanofi Lyon
Sanofi already has an anti-inflammation blockbuster in Dupixent, experience which could help bring C4X Discovery's candidate to market.

More from Business

More from Scrip